-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick -- The DBS test demonstrates a high correlation ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new ...
(RTTNews) - Savara Inc. (SVRA), a biopharmaceutical company, Thursday announced that it has introduced the aPAP ClearPath Dried Blood Spot Test in the U.S. This new test builds on its prior ...
CHICAGO - Savara Inc. (NASDAQ:SVRA), a $737 million market cap biotechnology company with strong financial health metrics according to InvestingPro, announced that its partner TrilliumBiO will present ...
The simple, no-cost, and noninvasive test is now available to physicians in the U.S. Company launches campaign in the U.S. to raise awareness of the rare autoimmune lung disease and need for early ...
Savara will also present data on its investigational treatment molgramostim, including an oral presentation on the drug’s efficacy according to aPAP severity and a poster examining relationships ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback